Market Overview

Anti-Neprilysin Drug Market is projected to achieve a value of USD 1,263 Million in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 2,183 Million by 2033 with a CAGR of 4.9% during the forecast period 2023-2033.

Anti-Neprilysin drug are mostly used in the treatment of acute heart failure. Hart failure is chronic progressive condition of heart muscles is unable to pump enough amount of blood to the body parts. The most widely used Anti-Neprilysin drug medication is Sacubitril/valsartan, available under the brand name Entrest. It is composed of the neprilysin inhibiting agent sacubitril and the angiotensin receptor blocking drug valsartan.

The increasing the prevalence of diseases like Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others drive the market growth in the forecasted period. Additionally, rising the incidences of heart diseases, increasing the government support for awareness campaign, robust research and development investment will fuel to drive the Anti-Neprilysin drug market.

For instance, as on June 2, 2022, Cipla Inc., an India-based biopharmaceutical and medical company, announced the commercial operation of additional capacity of captive renewable energy power plants in Maharashtra and Karnataka, India. This initiative is designed to fulfill the company's green energy demands for their manufacturing facilities located in Kurkumbh and Patalganga, both situated in India, as well as their research and development center in Maharashtra. It will effectively replace approximately 70% of the total energy consumption for these units with eco-friendly, renewable energy sources.

COVID 19 pandemic shown the negative Impacts on the growth of Anti-Neprilysin drug market. During the COVID-19 pandemic worldwide lockdown was imposed. As a COVID patient increased governments banned all transportation, restriction on vising of regular follow-up patients in hospital, it will impact on the patient treatment having chronic diseases and delay in elective or non-elective surgeries.

For instance, according to an article published in July 2022, in PubMed, a free search engine for biological databases and medical reports, it was reported that approximately 2.3 million cancer surgeries were delayed on a global scale during the early stages of the COVID-19 pandemic. These delays in cancer surgeries were primarily a consequence of the strain COVID-19 imposed on hospital resources and the heightened concerns regarding the increased risk of pulmonary complications linked to COVID-19 among cancer patients. 

Market Scope

Market Dynamics

The growth of the Anti-Neprilysin drug market is significantly driven by increasing prevalence of acute heart failure, an upsurge in government support and surveillance at both national and global levels. Furthermore, substantial investments by major industry players worldwide and increased government funding have played a pivotal role propelling the growth of the market.

For instance, as on the data published in September 2020, by PubMed, a free search engine for biological databases and medical reports, Heart failure impacts over 64 million individuals annually on a global scale. Addressing this condition's social and economic challenges has emerged as a significant public health priority worldwide.

Furthermore, increasing the product approval given by the regulatory bodies propelling the growth of Anti-Neprilysin drug market. For instance, in February 2015, Novartis International AG a drug manufacturing company announced that the U.S. Food and Drug Administration (FDA) granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). This decision is taken to accelerate the review of therapy or medication which offers a more safety and effectiveness in the treatments, diagnosis and preventions of serious conditions.

However, cost of therapy and the substantial expenses associated with research and development and the extended timeframe needed to bring a new drug in market could potentially impede the growth of the Anti-Neprilysin drug market.

Overall, with the help of existing and modern treatment therapy the Market is expected to witness significant growth in the coming years, driven by the introduction of new therapies and an increasing demand for effective treatments.

Market- Drug Type Analysis

By Drug Type, the Anti-Neprilysin drug Market is Categories into Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others. The Sacubitril segment accounts for the largest share of around 58% of the Market in 2022.

Sacubitril dominate the market because the drug has reduced the rate of cardiovascular death and reduce the hospitalization rate related to heart failure.  Globally, the only the drug combination of sacubitril and valsartan use effectively in the treatment of heart failure patient having reduce ejection fraction, which also boost the market growth.

Market Indication Analysis

By Indication, the Anti-Neprilysin drug Market is Categories into Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others. The Acute Heart Failure segment accounts for the largest share of around 51% of the Market in 2022.

Increasing the prevalence of chronic diseases, unhealthy lifestyle habits, smoking and heavy alcohol use, lack of physical activity are factors expected to lead the highest growth Rate for this segment during the forecast period.

Moreover, Hypertension is the second segment dominate the market. Anti-Neprilysin drug drugs are a new class of drugs useful in the treatment of hypertension. The drug is effective in lowering blood pressure and can be used in people with and without heart failure. Moreover, extended research is required to determine the long-term safety and efficacy of Anti-Neprilysin drug drugs in hypertension.

Market Distribution Channel Analysis

By Distribution Channel, the Anti-Neprilysin drug Market is Categories into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital segment accounts for the largest share of around 53% of the Market in 2022.

Increasing the healthcare facilities, increasing the admission of patients, most of clinical trials initiated in hospital, convenience and easy accessibility, fuel to drive the segment. Moreover, government gives subsidies to needy or poor patients in chronic disease propel the growth of segment.

Market Regional Analysis

North America dominate the Anti-Neprilysin drug Market with the highest revenue generating market with share of more than 41%. The North America dominate this market due to the increasing technological advancements, increasing research and development in the region.

Europe having the second-largest market share in Market due to well establishes healthcare centers, increase in product developments by various organization significantly contribute to expand the market.

Asia-Pacific is estimated the fastest growing CAGR in Anti-Neprilysin drug Market in forecasted period. This is due to increasing government initiatives and policies, the increasing population rise in India and China upsurge the chronic patients leading to increase the sale in market.

Competitive Analysis

The Anti-Neprilysin drug Market is dominated by a few large companies, such as Novartis AG, BIOPROJET, Pharmaleads SA, Cipla Inc, Oceanic Pharmachem Pvt. Ltd., Theravance Biopharm

There Are Some Of The Recent Developments Of The Market:

March 2021, Stragen Pharma SA, a Switzerland-based biopharmaceutical company, started enrollment of healthy volunteers in a phase II trial of STR-324 for postoperative pain. STR-324 is an anti-nephrilysin investigational new drug (IND) candidate.

January 18, 2023, Cipla Inc., an India-based biopharmaceutical and medical company, announced the launch of Cippoint, a point-of-care testing device. The device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers.

By Drug Type

·         Sacubitril

·         TD-0714

·         STR-324

·         PL-265

·         LHW-090

·         Others

By Indication

·         Acute Heart Failure

·         Cancer Pain

·         Hypertension

·         Alzheimer’s Disease

·         Others

By Distribution Channel

·         Hospitals Pharmacies

·         Retail Pharmacies

·         Online Pharmacies